You are here

  • Home
  • Archive
  • Volume 6, Issue 5
  • Review: angiotensin converting enzyme inhibitors are beneficial in type 1 diabetes mellitus and microalbuminuria regardless of baseline risk factor status

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: angiotensin converting enzyme inhibitors are beneficial in type 1 diabetes mellitus and microalbuminuria regardless of baseline risk factor status

https://doi.org/10.1136/ebm.6.5.146

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Ann Intern Med 134, 370. The ACE Inhibitors in Diabetic Nephropathy Trialist Group.. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.. Mar 6;. :. –9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with type 1 diabetes mellitus and microalbuminuria, what is the effect of angiotensin converting enzyme (ACE) inhibitors independent of confounding variables?

    Data sources

    Studies were identified by searching Medline and bibliographies of relevant papers and by contacting authors.

    Study selection

    Studies were selected if they included ≥10 patients with type 1 diabetes and microalbuminuria (defined as having an albumin excretion rate of 20 to 200 μg/minute, or approximately 30 to 300 mg/day, who were judged not to be hypertensive at the time of the original trial), had a placebo or non-intervention control group, had follow up ≥1 year, and measured albumin excretion rate at baseline and at ≥1 follow up visit.

    Data extraction

    Authors were contacted to provide individual patient data on age, duration of diabetes, sex, baseline treatment assignment, albumin excretion rate at baseline and follow up, blood pressure, and glycaemic control.

    Main results

    12 studies …

    View Full Text

    Footnotes

    • Source of funding: In part, Zeneca Pharmaceuticals

    • For correspondence: Dr N Chaturvedi, Department of Epidemiology and Public Health, Imperial College at St Mary's Norfolk Place, London W2 1PG, UK. Fax +44 (0)207 594 3392.